Zhu Rongping, Xiao Juan, Luo Diteng, Dong Mingjun, Sun Tian, Jin Junfei
Laboratory of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi, People's Republic of China; Emergency Traumatic Surgery, The Affiliated Ganzhou Hospital of Nanchang University (Ganzhou People's Hospital), Ganzhou 341000, Jiangxi, People's Republic of China.
Laboratory of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi, People's Republic of China; China-USA Lipids in Health and Disease Research Center, Guilin Medical University, Guilin 541001, Guangxi, People's Republic of China; Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Guilin Medical University, Guilin 541001, Guangxi, People's Republic of China.
Gastroenterol Hepatol. 2019 Dec;42(10):614-621. doi: 10.1016/j.gastrohep.2019.06.007. Epub 2019 Sep 5.
AKR1B10, first cloned from liver cancer tissues, has recently been reported to be up-regulated significantly in hepatocellular carcinoma (HCC) tissues, but the relationship between serum level of AKR1B10 and the risk of HCC is not understood.
170 HCC patients and 120 health donors from October 2014 to March 2017 were recruited in the affiliated hospital of Guilin Medical University. Serum AKR1B10 in all cases were detected and in 30 HCC patients were analyzed preoperatively and postoperatively by Time-resolved fluoroimmunoassay.
The level of serum AKR1B10 was significantly higher in HCC patients (1800.24±2793.79) than in health donors (129.34±194.129), and downregulation of serum AKR1B10 in HCC patients was observed after hepatectomy. When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ=6.295, P=0.012), ALT (χ=18.803, P=0.000), AST (χ=33.421, P=0.000), tumor nodule number (χ=6.777, P=0.009), cirrhosis (χ=43.458, P=0.000), and tumor size (χ=6.042, P=0.014) in the Chi-square test.
Diagnosis of HCC could be improved using the both predictors of serum AKR1B10 and AFP. AKR1B10 was thus considered to be a new serological biomarker for HCC.
AKR1B10最初是从肝癌组织中克隆出来的，最近有报道称其在肝细胞癌（HCC）组织中显著上调，但血清AKR1B10水平与HCC风险之间的关系尚不清楚。
2014年10月至2017年3月，桂林医学院附属医院招募了170例HCC患者和120名健康献血者。检测所有病例的血清AKR1B10，并对30例HCC患者术前和术后进行时间分辨荧光免疫分析。
HCC患者血清AKR1B10水平（1800.24±2793.79）显著高于健康献血者（129.34±194.129），肝切除术后HCC患者血清AKR1B10水平下调。当根据血清AKR1B10水平（≥232.7pg/ml）对样本进行分组时，在卡方检验中血清AKR1B10与血清甲胎蛋白（χ=6.295，P=0.012）、谷丙转氨酶（χ=18.803，P=0.000）、谷草转氨酶（χ=33.421，P=0.000）、肿瘤结节数（χ=6.777，P=0.009）、肝硬化（χ=43.458，P=0.000）和肿瘤大小（χ=6.042，P=0.014）呈正相关。
联合使用血清AKR1B10和甲胎蛋白这两个预测指标可提高HCC的诊断水平。因此，AKR1B10被认为是一种新的HCC血清生物标志物。
